Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection.
Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.
Mahajan
Tina Dewan
TD
Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hooker
Roderick
R
Maher
Lisa
L
Brown
Geri
G
Reimold
Andreas
A
D000069594:Abatacept; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000821:virology; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D018501:Antirheumatic Agents; D018796:Immunoconjugates; D000069594:Abatacept